Biotech startup Gliknik lands $25M licensing deal with Pfizer [Startup Roundup]

Have news for the Startup Roundup? Get in touch.

who’s getting funded?

TNI Biotech, Inc., based in Bethesda, has raised $2.8 million in equity, according to SEC filings. The biotech company develops immunotherapy treatments for cancer and autoimmune diseases.
FiscalNote, based in College Park, has raised $1.2 million in seed funding “from First Round Capital’s Dorm Room Fund, New Enterprise Associates and Mark Cuban,” according to CNN. The startup, which hasn’t launched yet, is a platform for government legislation analysis.

who’s making moves?

Canton-based OrderUp has added 10 new restaurants to its Baltimore website. The startup facilitates food-ordering online in Baltimore and around the U.S. through its digital-franchising model. Read Technical.ly Baltimore’s story on OrderUp.
Biopharmaceuticals startup Gliknik, which develops new therapies for patients with cancer and immune disorders, has announced “a licensing agreement granting Pfizer exclusive worldwide rights to GL-2045, one of four programs in Gliknik’s portfolio,” according to a press release. Gliknik, based in the University of Maryland BioPark, receives an upfront payment of $25 million.

• Under the agreement terms, Pfizer “receives exclusive worldwide license and will be responsible for the development and commercialization of GL-2045,” which is “a cell-based biologic that acts like pooled human intravenous immunoglobulin (IVIG), thereby eliminating the need to collect, pool, and purify human blood product from tens of thousands of blood donors.”